Giuliani M, Rizzi A, Pagano M, Raveglia L, Saccani F, Di Lascia M
ACS Med Chem Lett. 2025; 16(2):317-326.
PMID: 39967626
PMC: 11831564.
DOI: 10.1021/acsmedchemlett.4c00559.
Yue R, Yang T, Niu D, Zeng Z, Wang X, Pan L
PLoS One. 2025; 20(2):e0318246.
PMID: 39965011
PMC: 11835338.
DOI: 10.1371/journal.pone.0318246.
Dietrich J, Kang A, Tielemans B, Verleden S, Khalil H, Langer F
Eur Respir Rev. 2025; 34(175).
PMID: 39909504
PMC: 11795288.
DOI: 10.1183/16000617.0080-2024.
Machahua C, Marti T, Dorn P, Funke-Chambour M
Respir Res. 2025; 26(1):44.
PMID: 39875887
PMC: 11776118.
DOI: 10.1186/s12931-025-03110-2.
Kadam A, Schnitzer J
Int J Mol Sci. 2024; 25(22).
PMID: 39596365
PMC: 11595013.
DOI: 10.3390/ijms252212300.
Vascular involvement in idiopathic pulmonary fibrosis.
Mondoni M, Rinaldo R, Ryerson C, Albrici C, Baccelli A, Tirelli C
ERJ Open Res. 2024; 10(6).
PMID: 39588083
PMC: 11587140.
DOI: 10.1183/23120541.00550-2024.
Targeting Autotaxin and Lysophosphatidic Acid in Pulmonary Fibrosis: Admilparant's Positive Results Show Continued Promise.
Molyneaux P, Spagnolo P
Am J Respir Crit Care Med. 2024; 211(2):148-150.
PMID: 39514842
PMC: 11812539.
DOI: 10.1164/rccm.202410-2018ED.
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF).
Aribindi K, Liu G, Albertson T
Expert Rev Clin Pharmacol. 2024; 17(9):817-835.
PMID: 39192604
PMC: 11441789.
DOI: 10.1080/17512433.2024.2396121.
MNK-driven eIF4E phosphorylation regulates the fibrogenic transformation of mesenchymal cells and chronic lung allograft dysfunction.
Walker N, Ibuki Y, McLinden A, Misumi K, Mitchell D, Kleer G
J Clin Invest. 2024; 134(16).
PMID: 39145446
PMC: 11324311.
DOI: 10.1172/JCI168393.
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis.
Volkmann E, Denton C, Kolb M, Wijsenbeek-Lourens M, Emson C, Hudson K
Eur Respir Rev. 2024; 33(172).
PMID: 39009409
PMC: 11262619.
DOI: 10.1183/16000617.0015-2024.
Hypoxia Promotes Invadosome Formation by Lung Fibroblasts.
Lebel M, Cliche D, Charbonneau M, Brochu-Gaudreau K, Adam D, Brochiero E
Cells. 2024; 13(13.
PMID: 38995003
PMC: 11240699.
DOI: 10.3390/cells13131152.
The Role of Lysophospholipid Metabolites LPC and LPA in the Pathogenesis of Chronic Obstructive Pulmonary Disease.
Zhou Q, Chen Y, Liang Y, Sun Y
Metabolites. 2024; 14(6).
PMID: 38921452
PMC: 11205356.
DOI: 10.3390/metabo14060317.
Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives.
Vancheri C, Sciacca E, Muscato G, Spicuzza L, Fruciano M, Gili E
Multidiscip Respir Med. 2024; 19.
PMID: 38869027
PMC: 11186439.
DOI: 10.5826/mrm.2024.982.
Lactate transport inhibition therapeutically reprograms fibroblast metabolism in experimental pulmonary fibrosis.
Ziehr D, Li F, Parnell K, Krah N, Leahy K, Guillermier C
bioRxiv. 2024; .
PMID: 38712233
PMC: 11071479.
DOI: 10.1101/2024.04.25.591150.
ERS International Congress 2023: highlights from the Basic and Translational Sciences Assembly.
Reddy K, Bizymi N, Schweikert A, Ananth S, Lim C, Lodge K
ERJ Open Res. 2024; 10(2).
PMID: 38686182
PMC: 11057505.
DOI: 10.1183/23120541.00875-2023.
Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis.
Li Y, Jiang C, Zhu W, Lu S, Yu H, Meng L
Sci Prog. 2024; 107(2):368504241247402.
PMID: 38651330
PMC: 11036936.
DOI: 10.1177/00368504241247402.
Untargeted metabolomics reveals that declined PE and PC in obesity may be associated with prostate hyperplasia.
Fan G, Guan X, Guan B, Zhu H, Pei Y, Jiang C
PLoS One. 2024; 19(4):e0301011.
PMID: 38640132
PMC: 11029648.
DOI: 10.1371/journal.pone.0301011.
Autotaxin inhibition attenuates the aortic valve calcification by suppressing inflammation-driven fibro-calcific remodeling of valvular interstitial cells.
Yoon D, Choi B, Kim J, Kim E, Chung S, Min H
BMC Med. 2024; 22(1):122.
PMID: 38486246
PMC: 10941471.
DOI: 10.1186/s12916-024-03342-x.
Identification of inflammation-related biomarkers in keloids.
Wang X, Wang X, Liu Z, Liu L, Zhang J, Jiang D
Front Immunol. 2024; 15:1351513.
PMID: 38444850
PMC: 10912164.
DOI: 10.3389/fimmu.2024.1351513.
Involvement of Lysophospholipids in Pulmonary Vascular Functions and Diseases.
Kume H, Harigane R, Rikimaru M
Biomedicines. 2024; 12(1).
PMID: 38255229
PMC: 10813361.
DOI: 10.3390/biomedicines12010124.